Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
99
Views
44
CrossRef citations to date
0
Altmetric
Review

Emerging azole antifungals

Anne Chen Wayne State University, Detroit Medical Center, 3990 Harper Street, 5 Hudson, Detroit, MI 48201, USA
&
Jack D Sobel Wayne State University, Detroit Medical Center, 3990 Harper Street, 5 Hudson, Detroit, MI 48201, USA
Pages 21-33 | Published online: 22 Apr 2005

Bibliography

  • ARMSTRONG GL, CONN LA, PINNER RW: Trends in infectious disease mortality in the United States during the 20th century. JAMA (1999) 281(1):61–66.
  • DISMUKES WE, PAPPAS PG, SOBEL JD: Clinical Mycology. Oxford University Press, London (2003):23–29.
  • PINNER RW, TEUTSCH SM, SIMONSEN L et al.: Trends in infectious diseases mortality in the United States. JAMA (1996) 275(3):189–193.
  • MCNEIL MM, NASH SL, HAJJEH RA et al: Trends in mortality due to invasive mycotic diseases in the United States,1980-1997. Clin. Infect. Dis. (2001) 33(5):641–647.
  • BANERJEE SN, EMORI TG, CULVER DH et al.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System. Am. J. Med. (1991) 91(3B):586–589.
  • PFALLER MA, JONES RN, DOERN GV et al.: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. (2000) 44(3):747–751.
  • HAJJEH RA, SOFAIR A, HARRISON L: Fluconazole resistance among Candida bloodstream isolates: incidence and correlation with outcome from a population-based study. Abstracts of the 39th Meeting of the Infectious Diseases Society of America. (2001) San Francisco, CA, Abstract 641.
  • COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N Engl. J. Med. (1994) 330(4):263–272.
  • SANATI H, BELANGER P, FRATTI R et al: A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. (1997) 41(11):2492–2496.
  • WILSON LS, REYES CM, STOLPMAN M et al.: The direct cost and incidence of systemic fungal infections. Value Health (2002) 5(1):26–34.
  • DENNING DW: Diagnosis and management of invasive aspergillosis.Curr. Clin. Top. Infect. Dis. (1996) 16:277–299.
  • DENNING DW: Invasive aspergillosis. Clin. Infect. Dis. (1998) 26(4):781–803.
  • TEDDER M, SPRATT JA, ANSTADT MP et al.: Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg. (1994) 57(4):1044–1050.
  • NGUYEN MH, PEACOCK JE JR, TANNER DC et al.: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. (1995) 155(22):2429–2935.
  • EDMOND MB, WALLACE SE, MCCLISH DK et al.: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29(2):239–244.
  • WENZEL RP, EDMOND MB: Severe sepsis-national estimates. Crit. Care Med. (2001) 29(7):1472–1474.
  • GUDLAUGSSON O, GILLESPIE S, LEE K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. (2003) 37(9):1172–1177.
  • REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J. Med. (1994) 331(20):1325–1330.
  • SAAG MS, DISMUKES WE: Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. (1988) 32(1):1–8.
  • SUD IJ, CHOU DL, FEINGOLD DS: Effect of free fatty acids on liposome susceptibility to imiclazole antifitngals. Antimicrob. Agents Chemother. (1979) 16(5):660–663.
  • DE BRABANDER M, AERTS F, VAN CUTSEM J et al.: The activity of ketoconazole in mixed cultures of leukocytes and Candida albi cans. Sabouraudia. (1980) 18(3):197–210.
  • VAN DEN BOSSCHE H, WILLEMSENS G, COOLS W et el.: Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem. Soc. Iran.. (1983) 11(6):665–667.
  • MAERTENS JA: History of the development of azole derivatives. Clin Microbiol Infect. (2004) 10\(Suppl. 1):1–10.
  • PERFECT JR, LINDSAY MH, DREW RH: Adverse drug reactions to systemic antifitngals. Drug Saf (1992) 7:323.
  • LEWIS JH, ZIMMERMAN HJ, BENSON GD, ISHAK KG: Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. (1984) 86(3):503–513.
  • HITCHCOCK CA, WHITTLE PJ: Chemistry and mode of action of fluconazole. In: Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker Inc, New York (1993) pp.183–197.
  • GRANT SM, CLISSOLD SP: Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs (1990) 39(61:877–916.
  • CHA R, SOBEL JD: Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti-infect. Ther. (2004) 2(3):357–366
  • BRAMMER KW, FECZKO JM: Single-dose oral fluconazole in the treatment of vaginal candidosis. Ann. IVY Acad. Sri. (1988) 544:561–563.
  • STEIN GE, MUMMAW N: Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob. Agents Chemother. (1993) 37(1):89–92.
  • REEF SE, LEVINE WC, MCNEIL M et al.: Treatment options for vulvovaginal candidiasis, 1993. Clin. Infect. Dis. (1995) 20\(Supp1.1):580–590.
  • SOBEL JD, FARO S, FORCE RW et al.: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. (1998) 178(2):203–211.
  • DE WITS, WEERTS D, GOOSSENS H et al.: Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet (1989) 1(8641):746–748.
  • KOLETAR SL, RUSSELL JA, FASS RJ et al.: Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1990) 34(11):2267–2268.
  • WILCOX CM, ALEXANDER LN, CLARK WS et al.: Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology (1996) 110(6):1803–1809.
  • PHILLIPS P, SHAFRAN S, GARBER G et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur. j Clin. MicrobioL Infect. Dis. (1997) 16(5):337–345.
  • ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID D et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. (1996) 101(2):170–176.
  • MANAVATHU EK, CUTRIGHT JL, CHANDRASEKAR PH: Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. (1998) 42(11):3018–3021.
  • NEGRONI R, ARECHAVALA AI: Itraconazole: pharmacokinetics and indications. Arch. Med. Res. (1993) 24(4):387–393.
  • HARIA M, BRYSON HM, GOA KL: Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs (1996) 51(4):585–620.
  • DE BEULE K, VAN GESTEL J: Pharmacology of itraconazole. Drugs. (2001) 61 (Supp1.1):27–37.
  • BARONE JA, MOSKOVITZ BL, GUARNIERI J: Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42(7):1862–1865.
  • VAZQUEZ JA: Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Chn. Trials (2000) 1(1):47–59.
  • HERBRECHT, R: Voriconazole therapeutic review of a new azole antifungal. Expert Rev. Anti-infect. Ther. (2004) 2(4):485–497.
  • BARCHIESI F, RESTREPO M, MCGOUGH DA, RINALDI MG: In vitro activity of a new antifungal triazole: UK-109,496. Interscience Conference on Antimicrob. Agents Chemother. (1995), 35th (Abs F71). 30
  • OAKLEY KL, MOORE CB, DENNING DW: In-vitro activity of voriconazole against Aspergillus spp. and comparing itraconazole and amphotericin B. J. Antimicrob. Chemother. (1998) 42(1):91–94.
  • VERWEIJ PE, MENSINK M, RUS A et al: In-vitro activities of amphotericin B, itraconazole and voriconazole a clinical and environmental Aspergillus fumigatus isolates. Antimicrob. Chemother. (1998) 42(3):389–392.
  • ESTRELLAM C, TUDELAJL R, MELLADO E et al: Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole, amphotericin B against clinical isolates of Aspergillus fumigatus. Antimicrob. Chemother. (1998) 42(4):531–533.
  • GHANNOUM MA, OKOBULE-WONODI I, BHAT N et al: Antifitngal activity of voriconazole (UK-109,496), fluconazole and amphtericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. Chemother. (1999) 11:34–39.
  • HITCHCOCK CA, ANDREWS RJ, LEWIS BGH, TROKE PF: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with cryptococcus. Interscience Conference on Antimicrob. Agents Chemother. (1995),35th (AbsF75).
  • VAN T HEK LG, VERWEIJ PE, WEEMAES CM, VAN DALEN R, YNTEMA JB, MEIS JF: Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am. J. Respir. Crit. Care Med. (1998) 157(5 Pt 1):1694–1696.
  • ARIKAN S, LOZANO-CHIU M, PAETZNICK V et al.: Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol (1999) 37(12):3946–3951.
  • ESPINEL-INGROFF A: In vitro activity ofthe new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol (1998) 36(1):198–202.
  • MCGINNIS MR, PASARELL L, SUTTON DA et al.: In vitro activity of voriconazole against selected fungi. Med Mycol (1998) 36(4):239–242.
  • CLANCY CJ, NGUYEN MH: In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. j Clin. Microbiol. Infect. Dis. (1998) 17(8):573–575.
  • VORA S, PURIMETLA N, BRUMMER E, STEVENS DA: Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony- stimulating factor. Antimicrob. Agents Chemother. (1998) 42(0907–1010.
  • LOZANO-CHIU M, ARIKAN S, PAETZNICK VL et al.: Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J. Clin. Microbiol (1999) 37(9):2755–2759.
  • NGUYEN MH, YU CY: Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. (1998) 42(2):253–256.
  • JOHNSON EM, SZEKELY A, WARNOCK DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. (1998) 42(61:741–745.
  • SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. Clin. Microbiol Rev. (1999) 12:40–79.
  • WILDFEUER A, SEIDL HP, PAULE I, HABERREITER A: In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41: 309–319.
  • PFALLER MA, ZHANG J, MESSER SA et al.: In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neofirmans from the United States and Africa. Antimicrob. Agents Chemother. (1999) 43(1):169–171.
  • RADFORD SA, JOHNSON EM, WARNOCK DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. (1997) 41(4):841–843.
  • DANAHER PJ, WALTER EA: Successful treatment of chronic meningitis caused by Scedosporium apiospermum with oral voriconazole. Mayo Clin. Proc. (2004) 79(5):707–708.
  • HOWDEN BP, SLAVIN MA, SCHWARER AP, MUCH AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. j Clin. Microbiol Infect. Dis. (2003) 22(2):111–113.
  • MUNOZ P, MARIN M, TORNERO P et al.: Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. (2000) 31(61:1499–1501.
  • NESKY MA, MCDOUGAL EC, PEACOCK JE JR: Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. (2000) 31(3):673–677.
  • SABO JA, ABDEL-RAHMAN SM: Voriconazole: a new triazole antifungal. Ann. Pharmacother. (2000) 34(9):1032–1043.
  • HOFFMAN HL, ERNST EJ, KLEPSER ME: Novel triazole antifungal agents. Expert Opin. Investig. Drugs. (2000) 9(3):593–605.
  • JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630–637.
  • TROKE PF, BRAMMER KW, HITCHCOCK CA et el.: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidasis models and early clinical efficacy in candidiasis. Interscience Conference on Antimicrob. Agents Chemother. (1995), 35th (Abs F73).
  • HITCHCOCK CA, ANDREWS RJ, LEWIS BGH et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with aspergillus. Interscience Conference on Antimicrob. Agents Chemother. (1995) 35th (Abs F74).
  • ALLY R, SCHURMANN D, KREISEL W et al: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. (2001) 33(9):1447–1454.
  • WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. J. Med. (2002) 346(4):225–234.
  • HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl. J. Med. (2002) 347(6):408–415.
  • HOFFMAN HL, RATHBUN RC: Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs. (2002) 11(3):409–429.
  • MOUDGAL VV, SOBEL JD: Antifitngal drugs in pregnancy: a review. Expert Opin. Drug Saf (2003) 2(5):475–483.
  • RUBIN ZA, SOMANI J: New options for the treatment of invasive fungal infections. Semin. Oncol (2004) 31(2 Suppl. 4):91–98.
  • LAW D, MOORE CB, DENNING DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41:2310–2311.
  • GALGIANI JN, LEWIS ML: In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. (1997) 41:180–183.
  • OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. (1997) 41:1124–1126.
  • MARCO F, PFALLER MA, MESSER SA et al.: In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia (1998) 141:73–77.
  • ESPINEL-INGROFF A: Comparison ofin vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol (1998) 36:2950–2956.
  • FOTHERGILL AW, SUTTON DA, RINALDI MG: An in vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi. 36th Interscience Conference on Antimicrob. Agents Chemother. (1996).
  • SANCHE SE, FOTHERGILL AW, RINALDI MG: Interspecies variation of the suceptibility of Fusarium species to Schering 56592 in vitro. 37th Interscience Conference on Antimicrob. Agents Chemother, (1997) Abstract No. E–66.
  • LOZANO-CHIU MS, ARIKAN VL et al.: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43:589–591.
  • SUTTON DA: Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr Opin Infect Dis. (2002) 15(6):575–582.
  • MELLINGHOFF IK, WINSTON DJ, MUKWAYA G, SCHILLER GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. (2002) 15;34(12):1648–1650.
  • BARCHIESI F, ARZENI D, FOTHERGILL AW et al.: In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob. Agents Chemother. (2000) 44(1):226–229.
  • CACCIAPUOTI A, LOEBENBERG D, CORCORAN E et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. (2000) 44(8):2017–2022.
  • PFALLER MA, MESSER S, JONES RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (1997) 41:233–235.
  • GIRIJAVALLABHAN VM, SAKSENA AK, LOVEY RG et al.: Sch 56592, a novel orally active broad spectrum antifungal agent. 35th Interscience Conference on Antimicrob. Agents Chemother. (1995) Abs F61.
  • PATTERSON TF, KIRKPATRICK WR, MCATEE RK, LOEBENBERG D: Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis. 36th Interscience Conference on Antimicrob. Agents Chemother. (1996) Abs F98.
  • LUTZ JE, CLEMONS KV, STEVENS DA: Efficacy of SCH 56592 in amurine model of systemic coccidioidomyc 36th Interscience Conference on Antimicrob. Agents Chemother. (1996) Abs F100.
  • COURTNEY R, RADWANSKI E, LIM J, LAUGHLIN M: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. (2004) 48(3):804–808.
  • NOMEIR AA, KUMARI P, HILBERT MJ et al.: Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. (2000) 44(3):727–731.
  • COURTNEY R, SANSONE A. RADWANSKI E et al.: Relative oral bioavailability of three formulations of posaconazole in volunteers: basis for clinical development of the suspension. Clinical Microbioland Infect. (2003) 9(1):P1218.
  • HACHEM RY, RAAD II, AFIF CM: An open, non-comparative multicenter study to evaulate efficacy and posaconazole (5CH56592) in the treatment of invasive fungal infections (IFI) to or intolerant (I) to standard therapy (ST). Proceedings of the 40th Interscience Conference on Antimicrob. Agents Chemother. (2000):J1109.
  • KIRKPATRICK WR, MCATEE RK, FOTHERGILL AW et al.: Efficacy of 5CH56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44(3):780–782.
  • PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifitngal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. (2001) 45(3):857–869.
  • CACCIAPUOTI A. NAJVAR L, BOCANEGRA R et al.: Combination posaconazole and amphotericin B therapy against pulm aspergillosis and systemic candidiasis in mice. Clin. MicrobioL (2003) 9(1):P544.
  • HUNTER P: Clinical Microbiology and Infectious Diseases. Proceedings of the 13th European Congress. UK (2003) May 10–13.
  • Noxafil (Posaconazole Oral Suspension) Demonstrates significantly in patients with life-threatening fungal infection. Schering-Plough Corp. Press Release (2003) December 08.
  • Schering-Plough Analysts & portfolio managers meeting. Schering-Plough Corp. Company Presentation (2003) November 18.
  • Antifungal Drug Discovery & Development - Fifth International Summ NJ, USA. Everett N Meeting Report (2001), 28–29 March.
  • COURTNEY R, SANSONE A, RADWANSKI E et al.: Relative oral bioavailability if three formulations of posaconazole in volunteers: basis for clinical development of the suspension. Clin. Microbiol Infect. (2003) 9(1):P1218.
  • FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42:313–318.
  • HATA K, KIMURA J, MIKI H, TOYOSAWA T et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237–2242.
  • CLEMONS KV, STEVENS DA: Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. (2001) 45(12):3433–3436.
  • PFALLER MA, MESSER SA, HOLLIS RJ et al.: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (2002) 46(6):1723–1727.
  • LAVERDIERE M, HOBAN D, RESTIERI C et al.: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. (2002) 50(1):119–123.
  • PETRAITIENE R, PETRAITIS V, LYMAN CA et al.: Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2004) 48(4):1188–1196.
  • ANDES D, MARCHILLO K, STAMSTAD T, CONKLIN R: In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. (2003) 47(4):1193–1199.
  • NAKAMURA T, SAKAI R, SONODAET J et al.: ER-30346, a novel antifungal triazole: IV. Pharmacokinetics and toxicological studies in mice, rats, and dogs. 35th Interscience Conference on Antimicrob. Agents Chemother. (1995).
  • OHWADA J, MURASAKI C, YAMAZAKI T et al.: Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifitngals. Bioorg. Med. Chem. Lett. (2002) 12(19):2775–2780.
  • MIKAMO H, YIN XH, HAYASAKI Y et al.: Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy (2002) 48(1):7–9.
  • CAPILLA J, ORTONEDA M, PASTOR FJ et al.: In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother (2001) 45(9):2635–2637.
  • FERNANDEZ-TORRES B, CARRILLO AJ, MARTIN E et al.: In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. (2001) 45(9):2524–2528.
  • CAPILLA J, YUSTES C, MAYAYO E et al.: Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob. Agents Chemother. (2003) 47(6):1948–1951.
  • CARRILLO AJ, GUARRO J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. (2001) 45(7):2151–2153.
  • BARTROLI J, TURMO E, ALGUERO M et al.: UR-9825: A new triazole derivative with potent, broad spectrum ant 37th Interscience Conference on Antimicrob. Agents Chemother. (1997), E67.
  • URBINA JA, LIRA R, VISBAL G et al.: In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR- 9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. (2000) 44(9):2498–2502.
  • Albaconazole. Groupo Uriach. Company publication 2003, October 31.

Websites

  • http://www.uriach.com/english/imasdIimd.h tm. R&D pipeline. J Uriach & Cia SA. Company 22 October 2002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.